TY - JOUR T1 - Potential Spreading Dynamics of COVID-19 with Temporary Immunity – A Mathematical Modeling Study JF - medRxiv DO - 10.1101/2020.09.30.20204636 SP - 2020.09.30.20204636 AU - B Shayak AU - Mohit M Sharma Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/30/2020.09.30.20204636.abstract N2 - COVID-19 is caused by a hitherto nonexistent pathogen, hence the immune response to the disease is currently unknown. Studies conducted over the past few weeks have found that the antibody titre levels in the blood plasma of infected patients decrease over time, as is common for acute viral infections. Fully documented reinfection cases from Hong Kong, India, Belgium and USA, as well as credible to anecdotal evidence of second-time cases from other countries, bring into sharp focus the question of what profile the epidemic trajectories may take if immunity were really to be temporary in a significant fraction of the population. Here we use mathematical modeling to answer this question, constructing a novel delay differential equation model which is tailored to accommodate different kinds of immune response. We consider two immune responses here : (a) where a recovered case becomes completely susceptible after a given time interval following infection and (b) where a first-time recovered case becomes susceptible to a lower virulence infection after a given time interval following recovery, and becomes permanently immunized by a second infection. We find possible solutions exhibiting large number of waves of disease in the first situation and two to three waves in the second situation. Interestingly however, these multiple wave solutions are manifest only for some intermediate values of the reproduction number R, which is governed by public health intervention measures. For sufficiently low as well as sufficiently high R, we find conventional single-wave solutions despite the short-lived immunity. Our results cast insight into the potential spreading dynamics of the disease and might also be useful for analysing the spread after a vaccine is invented, and mass vaccination programs initiated.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe have received NO funding for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research does not involve human or animal subjects so no IRB approvals/exemptions required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThere is NO data referred to in the manuscript. ER -